医学
舒尼替尼
危险系数
肾细胞癌
内科学
肿瘤科
置信区间
相对风险
低风险
作者
Daniel Lee,Haley Gittleman,Chana Weinstock,Daniel L. Suzman,Erik Bloomquist,Sundeep Agrawal,Michael H. Brave,Jamie Leigh Brewer,Jaleh Fallah,Harpreet Singh,Shenghui Tang,Amna Ibrahim,Richard Pazdur,Julia A. Beaver,Laleh Amiri‐Kordestani
标识
DOI:10.1016/j.eururo.2023.05.030
摘要
Patients with intermediate/poor-risk metastatic renal cell carcinoma derive an overall survival benefit from immuno-oncology/tyrosine kinase inhibitor combinations, while data for favorable-risk remain immature.
科研通智能强力驱动
Strongly Powered by AbleSci AI